Aarkstore - Plantacor, Inc. - Product Pipeline Review - 2014

1
Plantacor, Inc. - Product Pipeline Review - 2014
Category Pharmaceuticals Healthcare

• Browse Complete Report -
• http//www.aarkstore.com/pharmaceuticals-healthcar
  e/63688/plantacor-inc-product-pipeline-review

2
Regado Biosciences, Inc. - Product Pipeline
Review - 2014
3
Summary

• Global Markets Directs, Plantacor, Inc. -
  Product Pipeline Review - 2014, provides an
  overview of the Plantacor, Inc.s pharmaceutical
  research and development focus.  This report
  provides comprehensive information on the current
  therapeutic developmental pipeline of Plantacor,
  Inc.s, complete with comparative analysis at
  various stages, therapeutics assessment by drug
  target, mechanism of action (MoA), route of
  administration (RoA) and molecule type. It also
  reviews latest updates, and featured news and
  press releases, along with special features on
  late-stage and discontinued projects.  "Plantaco
  r, Inc. - Product Pipeline Review - 2014" report
  features investigational drugs from across globe
  covering over 20 therapy areas and nearly 3,000
  indications. The report is built using data and
  information sourced from Global Markets Directs
  proprietary databases, Company/University
  websites, SEC filings, investor presentations and
  featured press releases from company/university
  sites and industry-specific third party sources,
  put together by Global Markets Directs team.

4
Summary

• Drug profiles/records featured in the report
  undergoes periodic updation following a stringent
  set of processes that ensures that all the
  profiles are updated with the latest set of
  information. Additionally, processes including
  live news deals tracking, browser based
  alert-box and clinical trials registries tracking
  ensure that the most recent developments are
  captured on a real time basis.  The report
  enhances decision making capabilities and help to
  create effective counter strategies to gain
  competitive advantage. It strengthens RD
  pipelines by identifying new targets and MOAs to
  produce first-in-class and best-in-class
  products.  Note Certain sections in the
  report may be removed or altered based on the
  availability and relevance of data for the
  indicated disease.

5
Scope

• - The report provides brief overview of
  Plantacor, Inc. including business description,
  key information and facts, and its locations and
  subsidiaries - The report reviews current
  pipeline of Plantacor, Inc.s human therapeutic
  division and enlists all their major and minor
  projects - The report features product
  description and descriptive mechanism of action
  for key pipeline products along with the
  products developmental history and major
  milestones  - Special feature on out-licensed
  and partnered product portfolio - The report
  summarizes all the dormant and discontinued
  pipeline projects - Latest company statement  -
  Latest news and deals relating to the Plantacor,
  Inc.s pipeline products

6
Reasons to buy

• - Evaluate Plantacor, Inc.s strategic position
  with total access to detailed information on its
  product pipeline - Assess the growth potential
  of Plantacor, Inc. in its therapy areas of
  focus - Identify new drug targets and
  therapeutic classes in the Plantacor, Inc.s RD
  portfolio and develop key strategic initiatives
  to reinforce pipeline in those areas - Exploit
  in-licensing opportunities by identifying windows
  of opportunity to fill portfolio gaps - Develop
  strategic initiatives by understanding the focus
  areas of Plantacor, Inc. and exploit
  collaboration and partnership opportunities -
  Identify emerging players with potentially strong
  product portfolio and create effective
  counter-strategies to gain competitive
  advantage - Plan mergers and acquisitions
  effectively by identifying the most promising
  pipeline of Plantacor, Inc. - Develop and design
  in-licensing and out-licensing strategies by
  identifying prospective partners with the most
  attractive projects to enhance and expand
  business potential and scope

7
Table of Content
List of Tables 3List of Figures 3Plantacor,
Inc. Snapshot 4Plantacor, Inc. Overview 4Key
Information 4Key Facts 4Plantacor, Inc. -
Research and Development Overview 5Key
Therapeutic Areas 5Plantacor, Inc. - Pipeline
Review 7Pipeline Products by Stage of
Development 7Pipeline Products - Monotherapy
8Plantacor, Inc. - Pipeline Products Glance
9Plantacor, Inc. - Early Stage Pipeline Products
9
8
Table of Content
Preclinical Products/Combination Treatment
Modalities 9Discovery Products/Combination
Treatment Modalities 10Plantacor, Inc. - Drug
Profiles 11C-Substituted Diindolylmethane
Derivatives 11Product Description 11Mechanism
of Action 11RD Progress 11CDIM-9 12Product
Description 12Mechanism of Action 12RD
Progress 12CDIM-1 13Product Description
13Mechanism of Action 13
9
List Of Tables

• Plantacor, Inc., Key Information 4Plantacor,
  Inc., Key Facts 4Plantacor, Inc. - Pipeline by
  Indication, 2014 6Plantacor, Inc. - Pipeline by
  Stage of Development, 2014 7Plantacor, Inc. -
  Monotherapy Products in Pipeline, 2014
  8Plantacor, Inc. - Preclinical, 2014
  9Plantacor, Inc. - Discovery, 2014 10Plantacor,
  Inc. - Pipeline by Target, 2014 16Plantacor,
  Inc. - Pipeline by Molecule Type, 2014
  17Plantacor, Inc. - Pipeline Products by
  Mechanism of Action, 2014 18

10
List of Figures

• Plantacor, Inc. - Pipeline by Top 10 Indication,
  2014 6Plantacor, Inc. - Pipeline by Stage of
  Development, 2014 7Plantacor, Inc. - Monotherapy
  Products in Pipeline, 2014 8Plantacor, Inc. -
  Pipeline by Top 10 Target, 2014 16Plantacor,
  Inc. - Pipeline by Top 10 Molecule Type, 2014
  17Plantacor, Inc. - Pipeline Products by Top 10
  Mechanism of Action, 2014 18

11
Related Reports

• Global Neurosurgery Market 2015-2019
• Active Pharmaceutical Ingredients (API) Market in
  India 2015-2019
• BrainStorm Cell Therapeutics Inc. (BCLI) -
  Financial and Strategic SWOT Analysis Review
• Ampio Pharmaceuticals, Inc. (AMPE) - Financial
  and Strategic SWOT Analysis Review
• MiMedx Group, Inc (MDXG) - Financial and
  Strategic SWOT Analysis Review

12
Related Reports

• Threshold Pharmaceuticals, Inc. (THLD) -
  Financial and Strategic SWOT Analysis Review
• MEI Pharma, Inc. (MEIP) - Financial and Strategic
  SWOT Analysis Review
• Titan Pharmaceuticals, Inc. (TTNP) - Financial
  and Strategic SWOT Analysis Review
• RedHill Biopharma Ltd. (RDHL) - Financial and
  Strategic SWOT Analysis Review
• Pharmaceuticals Healthcare Market Research
  Reports

13

• Plantacor, Inc. - Product Pipeline Review -
  2014Published Oct 2014 21 Pages
• "Plantacor, Inc. - Product Pipeline Review -
  2014" report features investigational drugs from
  across globe covering over 20 therapy areas and
  nearly 3,000 indications.
  Price

Format Price
PDF 1500
Site Licence 3000
Enterprise Wide Licence 4500
14
Contact Us
Office Office No. - 809, 8th Floor,B-Wing,
Mahaavir Icon, Plot No.- 89 90,
Sector-15,CBD-Belapur, Navi Mumbai
400614, Maharashtra, India. Telefax No 91 22
4127 6660 24/7 Online Support 91
9987295242 General Inquiries 91 - 22 2756 4953

• You Can Visit http//www.aarkstore.com
• OR Mail us at contact_at_aarkstore.com
• Blog
• http//www.aarkstore.com/blog/
• Conference
• http//conference.aarkstore.com/
• News
• http//www.aarkstore.com/news